查看文章

ability to predict PR individually, and when analyzed in combination with key prognostic factors. After identifying gene panels to predict PR, we evaluated the performance of the identical gene panel to discriminate patients with PM from those without metastasis by analyzing 210 patients from two clinical cohorts (a validation cohort, n= 142, a peritoneal metastasis evaluation cohort, n= 68). Results: Genome-wide transcriptomic profiling identified a 12-gene panel for robust prediction of PR in GC patients (AUC= 0.95; 95% CI: 0.89-0.98), which was successfully validated in an independent dataset (AUC= 0.86; 95% CI: 0.79-0.91). Examination of 216 tissue specimens from a training cohort allowed us to establish a 6-gene based risk prediction model (AUC= 0.72; 95% CI: 0.66-0.78), which was subsequently validated in an independent cohort of 111 GC patients (AUC= 0.76; 95% CI: 0.67-0.83). In both cohorts …